Clinical utility of rituximab in chronic graft-versus-host disease

Annals of Pharmacotherapy

Volumn 43, Issue 2, 2009, Pages 316-321

  Bates, Jill S ^a   Engemann, Ashley Morris ^a   Hammond, Julia M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CD20; Graft versus host disease; Monoclonal antibodies; Rituximab

Indexed keywords

CD20 ANTIGEN; CORTICOSTEROID; DACLIZUMAB; ETANERCEPT; PENTOSTATIN; RITUXIMAB; TACROLIMUS;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASTHENIA; B LYMPHOCYTE; CLINICAL TRIAL; COUGHING; DRUG BINDING; DRUG EFFICACY; DRUG FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LYMPHOCYTOPENIA; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; PRIORITY JOURNAL; PUVA; RASH; REVIEW; RHINITIS; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; STEROIDS; TRANSPLANTATION CONDITIONING;

EID: 60349083580     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L386     Document Type: Review

References (24)

1. Perez-Simon JA, Sanchez-Abarca I, Diez-Campelo M, Caballero D, San Miguel J. Chronic graft versus host disease pathogenesis and clinical management. Drugs 2006;66:1041-57.
2. Shlomchik WD. Graft versus host disease. Nat Rev Immunol 2007;7:340-52.
3. Weisdorf DJ. GVHD - the nuts and bolts. Hematology Am Soc Hematol Educ Program 2007;2007:62-7.
4. Shulman H, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
5. Bhushan V, Collins RH. Chronic graft-vs-host disease. JAMA 2003;290:2599-603.
6. Kim SS. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation. Ann Pharmacother 2007;41:1436-44. Epub 7 Aug 2007. DOI 10.1345/aph.1K179
7. US Department of Health and Human Services. First monoclonal antibody approved to treat cancer. www.fda.gov/bbs/topics/NEWS/NEW00601.html (accessed 2008 May 18).
8. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-42.
9. Product information. Rituxan (rituximab). San Francisco, CA: Biogen Idee, Inc. and Genentech USA, Inc., September 2008.
10. Morris SC, Cheek RL, Cohen P, Eisenberg RA. Allotype-specific immunoregulation of autoantibody production by host B cells in chronic graft versus host disease. J Immunol 1990;144:916-22.
11. Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-versus-host disease. Haematologica 2008;93:1702-11. Epub 25 Aug 2008. DOI 10.3324/haematol.13311
12. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft versus host disease and disease remission. Blood 2005;105:2973-8.
13. National Marrow Donor Program. Trends in allogeneic transplants. www.marrow.org/PHYSICIAN/URD-Search-and-Tx/Number-of-Al-logeneic-Tx-Perfor/ index.html (accessed 2008 Sept 13).
14. Cutler C, Miklos DB, Kim HT, et al. Rituximab for steroid-refractory chronic graft versus host disease. Blood 2006;108:756-62.
15. Akpek G, Lee SJ, Flowers ME, et al. Performance of a new clinical grading system for chronic graft versus host disease: a multicenter study. Blood 2003;102:802-9.
16. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007;40:273-7.
17. Carella AM, Biasco S, Nati S, Congiu A, Lerma E. Rituximab is effective for extensive steroid-refractory chronic graft vs host disease. Leuk Lymphoma 2007;48:623-4.
18. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft versus host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9:505-11.
19. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft versus host disease. Ann Intern Med 2000;133:275-9.
20. Benson DM, Smith MK, Krugh D, Devine SM. Successful therapy of chronic graft-versus-host disease manifesting as pure red cell aplasia with single-agent rituximab. Bone Marrow Transplant 2008;41:595-6.
21. Mohty M, Marchetti N, El-Cheikh J, Faucher C, Furst S, Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008;41:909-11.
22. Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft versus host disease. Leukemia 2006;20:172-3.
23. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody-treatment in 6 patients with therapy-refractory chronic graft versus host disease. Blood 2004;104:2603-6.
24. Martin PJ. Study design and endpoints in graft-versus-host-disease. Best Pract Res Clin Haematol 2008;21:357-72.